K
1.17
-0.08 (-6.50%)
| Previous Close | 1.25 |
| Open | 1.24 |
| Volume | 2,175,560 |
| Avg. Volume (3M) | 38,951,888 |
| Market Cap | 42,654,656 |
| Price / Book | 82.28 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.270 |
| Total Debt/Equity (MRQ) | 276.80% |
| Current Ratio (MRQ) | 0.290 |
| Operating Cash Flow (TTM) | -4.48 M |
| Levered Free Cash Flow (TTM) | -1.95 M |
| Return on Assets (TTM) | -151.41% |
| Return on Equity (TTM) | -1,544.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Klotho Neurosciences, Inc. | - | - |
AIStockmoo Score
-0.9
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | -0.88 |
|
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 50.23% |
| % Held by Institutions | 2.60% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |